Challenger Limited: Growth Momentum with Strategic Capital Realignment
Challenger Limited (ASX: CGF) continues to demonstrate strong traction in its retirement-focused investment business, supported by rising demand for annuity products. During the third quarter, total Life sales reached approximately AU$1.7 billion, reflecting a 19% increase, driven by solid performance across lifetime annuities (AU$289 million, up 18%) and offshore reinsurance annuities (AU$281 million, up 17%). Fixed-term annuity sales stood at AU$517 million, showing modest growth.
The company reported annuity net flows of AU$274 million, translating to a 1.7% quarterly book growth, while maintaining a strong capital position with a PCA ratio of 1.51 times. However, funds under management declined by 10% to AU$104.5 billion due to net outflows and adverse market movements.
Strategically, Challenger announced the redemption of its Capital Notes 3 at AU$100 per note, alongside a final distribution of AU$1.47 per note, payable in May 2026. This move aligns with its objective to optimise capital efficiency while sustaining long-term growth in the retirement income market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Challenger Limited: Growth Momentum with Strategic Capital Realignment
Challenger Limited (ASX: CGF) continues to demonstrate strong traction in its retirement-focused investment business, supported by rising demand for annuity products. During the third quarter, total Life sales reached approximately AU$1.7 billion, reflecting a 19% increase, driven by solid performance across lifetime annuities (AU$289 million, up 18%) and offshore reinsurance annuities (AU$281 million, up 17%). Fixed-term annuity sales stood at AU$517 million, showing modest growth.
The company reported annuity net flows of AU$274 million, translating to a 1.7% quarterly book growth, while maintaining a strong capital position with a PCA ratio of 1.51 times. However, funds under management declined by 10% to AU$104.5 billion due to net outflows and adverse market movements.
Strategically, Challenger announced the redemption of its Capital Notes 3 at AU$100 per note, alongside a final distribution of AU$1.47 per note, payable in May 2026. This move aligns with its objective to optimise capital efficiency while sustaining long-term growth in the retirement income market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au